John C Thomas Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for John C Thomas.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of John C Thomas. John C Thomas is Director in QLT INC/BC ($QLTI) and Director in NantKwest, Inc. ($NK) and in Medovex Corp. ($MDVX) and Director in Medovex Corp. ($MDVX) and in Virios Therapeutics, Inc. ($VIRI).
Latest Insider Trading Transactions of John C Thomas
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, MDVX, NK, NVLN, VIRI
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 23 2021 | VIRI | Virios Therapeutic ... | Thomas John C | Option Exercise | A | 6.50 | 7,875 | 51,188 | 7,875 | ||
| Jun 23 2021 | VIRI | Virios Therapeutic ... | Thomas John C | Option Exercise | A | 6.50 | 7,875 | 51,188 | 7,875 | ||
| Dec 11 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 10.83 | 42,592 | 461,122 | 207,477 | 250.1 K to 207.5 K (-17.03 %) |
| Aug 21 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 9.19 | 20,000 | 183,800 | 250,069 | 270.1 K to 250.1 K (-7.41 %) |
| Aug 13 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 9.34 | 20,000 | 186,800 | 270,069 | 290.1 K to 270.1 K (-6.89 %) |
| Aug 13 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 9.49 | 20,000 | 189,800 | 290,069 | 310.1 K to 290.1 K (-6.45 %) |
| Aug 13 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 10.55 | 210 | 2,216 | 310,069 | 310.3 K to 310.1 K (-0.07 %) |
| Aug 13 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 10.35 | 19,790 | 204,827 | 310,279 | 330.1 K to 310.3 K (-6.00 %) |
| Jun 11 2020 | NK | NantKwest, Inc. | Thomas John C | Director | Option Exercise | A | 6.21 | 100,000 | 621,000 | 100,000 | |
| Dec 16 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 3.14 | 10,000 | 31,400 | 330,069 | 340.1 K to 330.1 K (-2.94 %) |
| Dec 16 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 2.98 | 10,000 | 29,800 | 340,069 | 350.1 K to 340.1 K (-2.86 %) |
| Dec 16 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 2.48 | 10,000 | 24,800 | 350,069 | 360.1 K to 350.1 K (-2.78 %) |
| Dec 12 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 1.99 | 10,000 | 19,918 | 360,069 | 370.1 K to 360.1 K (-2.70 %) |
| Sep 09 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 1.24 | 13,956 | 17,305 | 370,069 | 384 K to 370.1 K (-3.63 %) |
| Sep 09 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 1.24 | 7,080 | 8,779 | 384,025 | 391.1 K to 384 K (-1.81 %) |
| Sep 09 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 1.25 | 2,964 | 3,705 | 391,105 | 394.1 K to 391.1 K (-0.75 %) |
| Jun 07 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Grant | A | 0.00 | 92,592 | 0 | 394,069 | 301.5 K to 394.1 K (+30.71 %) |
| Jun 07 2019 | NK | NantKwest, Inc. | Thomas John C | Director | Grant | A | 0.00 | 92,592 | 0 | 394,069 | 301.5 K to 394.1 K (+30.71 %) |
| Aug 13 2018 | NVLN | NOVELION THERAPEUT ... | Thomas John C | Director | Option Exercise | A | 3.33 | 10,000 | 33,300 | 10,000 | |
| Jun 11 2018 | NK | NantKwest, Inc. | Thomas John C | Director | Grant | A | 0.00 | 27,322 | 0 | 301,477 | 274.2 K to 301.5 K (+9.97 %) |
| Jan 03 2018 | NK | NantKwest, Inc. | Thomas John C | Director | Gift | G | 0.00 | 4,500 | 0 | 274,155 | 278.7 K to 274.2 K (-1.61 %) |
| Dec 19 2017 | MDVX | Medovex Corp. | Thomas John C | Director | Sell | P | 0.70 | 6,000 | 4,200 | 115,960 | 122 K to 116 K (-4.92 %) |
| Nov 01 2017 | MDVX | Medovex Corp. | Thomas John C | Director | Grant | A | 1.17 | 12,821 | 15,001 | 109,960 | 97.1 K to 110 K (+13.20 %) |
| Jun 21 2017 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.54 | 10,000 | 75,400 | 278,655 | 288.7 K to 278.7 K (-3.46 %) |
| Jun 21 2017 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.44 | 20,000 | 148,800 | 288,655 | 308.7 K to 288.7 K (-6.48 %) |
| Jun 21 2017 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.43 | 10,000 | 74,300 | 308,655 | 318.7 K to 308.7 K (-3.14 %) |
| Jun 13 2017 | NK | NantKwest, Inc. | Thomas John C | Director | Grant | A | 0.00 | 23,753 | 0 | 318,655 | 294.9 K to 318.7 K (+8.05 %) |
| Jun 01 2017 | NK | NantKwest, Inc. | Thomas John C | Director | Gift | G | 0.00 | 12,500 | 0 | 294,902 | 307.4 K to 294.9 K (-4.07 %) |
| Jan 17 2017 | MDVX | Medovex Corp. | Thomas John C | Grant | A | 1.38 | 21,739 | 30,000 | 97,139 | 75.4 K to 97.1 K (+28.83 %) | |
| Dec 27 2016 | QLTI | NOVELION THERAPEUT ... | Thomas John C | Director | Option Exercise | A | 8.65 | 9,600 | 83,040 | 9,600 | |
| Nov 29 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.50 | 6,168 | 46,260 | 309,621 | 315.8 K to 309.6 K (-1.95 %) |
| Nov 23 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.50 | 7,000 | 52,500 | 315,789 | 322.8 K to 315.8 K (-2.17 %) |
| Nov 23 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Sell | S | 7.50 | 13,000 | 97,500 | 322,789 | 335.8 K to 322.8 K (-3.87 %) |
| Jun 21 2016 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | A | 0.00 | 6,400 | 0 | 28,400 | |
| Jun 21 2016 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | A | 1.43 | 50,000 | 71,500 | 50,000 | |
| May 27 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Option Exercise | M | 0.22 | 277,725 | 60,016 | 0 | |
| May 27 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Buy | M | 0.22 | 277,725 | 60,016 | 335,789 | 58.1 K to 335.8 K (+478.31 %) |
| Mar 08 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Gift | G | 0.00 | 16,000 | 0 | 58,064 | 74.1 K to 58.1 K (-21.60 %) |
| Mar 08 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Gift | G | 0.00 | 2,775 | 0 | 74,064 | 76.8 K to 74.1 K (-3.61 %) |
| Mar 08 2016 | NK | NantKwest, Inc. | Thomas John C | Director | Gift | G | 0.00 | 15,736 | 0 | 76,839 | 92.6 K to 76.8 K (-17.00 %) |
| Jul 01 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | M | 3.30 | 12,500 | 41,250 | 0 | |
| Jul 01 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | M | 3.67 | 12,500 | 45,875 | 0 | |
| Jul 01 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Buy | M | 3.30 | 12,500 | 41,250 | 37,000 | 24.5 K to 37 K (+51.02 %) |
| Jul 01 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Buy | M | 3.67 | 12,500 | 45,875 | 24,500 | 12 K to 24.5 K (+104.17 %) |
| Jun 09 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | M | 0.00 | 6,000 | 0 | 0 | |
| Jun 09 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Option Exercise | M | 0.00 | 4,000 | 0 | 0 | |
| Jun 09 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Buy | M | 0.00 | 6,000 | 0 | 12,000 | 6 K to 12 K (+100.00 %) |
| Jun 09 2015 | QLTI | QLT INC/BC | Thomas John C | Director | Buy | M | 0.00 | 4,000 | 0 | 6,000 | 2 K to 6 K (+200.00 %) |
Page: 1